Opportunistic infection
| Opportunistic infection | |
|---|---|
| Classification and external resources | |
| MeSH | D009894 |
An opportunistic infection is an infection caused by pathogens (bacteria, viruses, fungi, or protozoa) that take advantage of an opportunity not normally available, such as a host with a weakened immune system, an altered microbiota (such as a disrupted gut flora), or breached integumentary barriers. Many of these pathogens do not cause disease in a healthy host that has a normal immune system. However, a compromised immune system, a penetrating injury, or a lack of competition from normal commensals presents an opportunity for the pathogen to infect.
Cause
Immunodeficiency or immunosuppression can be caused by:
- Malnutrition
- Fatigue
- Recurrent infections
- Immunosuppressing agents for organ transplant recipients
- Advanced HIV infection
- Chemotherapy for cancer
- Genetic predisposition
- Skin damage
- Antibiotic treatment leading to disruption of the physiological microbiome, thus allowing some microorganisms to outcompete others and become pathogenic (e.g. disruption of intestinal flora may lead to Clostridium difficile infection
- Medical procedures
- Pregnancy Further information: Susceptibility and severity of infections in pregnancy
- Ageing
- Leukopenia (i.e. neutropenia and lymphocytopenia)
The lack of or the disruption of normal vaginal flora allows the proliferation of opportunistic microorganisms and will cause the opportunistic infection - bacterial vaginosis.[1][2][3][4]
Types of infections
A partial listing of opportunistic organisms includes:
- Aspergillus sp.
- Candida albicans
- Clostridium difficile
- Coccidioides immitis
- Cryptococcus neoformans
- Cryptosporidium
- Cytomegalovirus
- Geomyces destructans (bats)
- Histoplasma capsulatum
- Isospora belli
- Polyomavirus JC polyomavirus, the virus that causes Progressive multifocal leukoencephalopathy.
- Kaposi's Sarcoma caused by Human herpesvirus 8 (HHV8), also called Kaposi's sarcoma-associated herpesvirus (KSHV)
- Legionnaires' Disease (Legionella pneumophila)
- Microsporidium
- Mycobacterium avium complex (MAC) (Nontuberculosis Mycobacterium)
- Mycobacterium tuberculosis
- Pneumocystis jirovecii, previously known as Pneumocystis carinii f. hominis
- Pseudomonas aeruginosa
- Salmonella
- Staphylococcus aureus
- Streptococcus pneumoniae
- Streptococcus pyogenes
- Toxoplasma gondii
Prophylaxis (Prevention)
Since opportunistic infections can cause severe disease, much emphasis is placed on measures to prevent infection. Such a strategy usually includes restoration of the immune system as soon as possible, avoiding exposures to infectious agents, and using antimicrobial medications ("prophylactic medications") directed against specific infections.
Restoration of Immune System
- In patients with HIV, starting antiretroviral therapy is especially important for restoration of the immune system and reduces the incidence of all opportunistic infections[5][6]
- In patients undergoing chemotherapy, completion of and recovery from treatment is the primary method for immune system restoration. In a select subset of high risk patients, granulocyte colony stimulating factors (G-CSF) can be used to aid immune system recovery.[7][8]
Infectious Exposures to Avoid[9]
- Cat feces (E.g. cat litter): source of Toxoplasma gondii, Bartonella spp.
- Eating undercooked meat or eggs, unpasteurized dairy products or juices
- Potential sources of tuberculosis (high risk healthcare facilities, regions with high rates of tuberculosis, patients with known tuberculosis)
- Contact with farm animals, especially those with diarrhea: source of Toxoplasma gondii, Cryptosporidium parvum
- Soil/dust in areas where there is known histoplasmosis, coccidiomycosis
- Reptiles, chicks, ducklings: source of Salmonella spp.
- Unprotected sexual intercourse with individuals with known sexually transmitted infections. Any sex practice that might result in oral exposure to feces.
Prophylactic Medications
Individuals at higher risk are often prescribed prophylactic medication to prevent an infection from occurring. A patient's risk level for developing an opportunistic infection is approximated using the patient's CD4 T-cell count and sometimes other markers of susceptibility. Common prophylaxis treatments include the following:[10]
| Infection | When to Give Prophylaxis | Agent |
|---|---|---|
| Pneumocystis jirovecii | CD4 < 200 cells/mm3 or oropharyngeal candidasis (thrush) | TMP-SMX |
| Toxoplasma gondii | CD4 < 100 cells/mm3 and positive Toxoplasma gondii IgG immunoassay | TMP-SMX |
| Mycobacterium avium complex | CD4 < 50 | Azithromycin |
Treatment
Treatment depends on the type of opportunistic infection, but usually involves different antibiotics.
Veterinary treatment
Opportunistic infections caused by Feline Leukemia Virus and Feline immunodeficiency virus retroviral infections can be treated with Lymphocyte T-Cell Immune Modulator.
 |
Wikimedia Commons has media related to Opportunistic pathogens. |
References
- ↑ Africa, Charlene; Nel, Janske; Stemmet, Megan (2014). "Anaerobes and Bacterial Vaginosis in Pregnancy: Virulence Factors Contributing to Vaginal Colonisation". International Journal of Environmental Research and Public Health 11 (7): 6979–7000. doi:10.3390/ijerph110706979. ISSN 1660-4601. PMC 4113856. PMID 25014248.
- ↑ Mastromarino, Paola; Vitali, Beatrice; Mosca, Luciana (2013). "Bacterial vaginosis: a review on clinical trials with probiotics" (PDF). New Microbiologica 36: 229–238. PMID 23912864.
- ↑ Mastromarino, Paola; Vitali, Beatrice; Mosca, Luciana (2013). "Bacterial vaginosis: a review on clinical trials with probiotics" (PDF). New Microbiologica 36: 229–238. PMID 23912864.
- ↑ Knoester, M.; Lashley, L. E. E. L. O.; Wessels, E.; Oepkes, D.; Kuijper, E. J. (2011). "First Report of Atopobium vaginae Bacteremia with Fetal Loss after Chorionic Villus Sampling". Journal of Clinical Microbiology 49 (4): 1684–1686. doi:10.1128/JCM.01655-10. ISSN 0095-1137.
- ↑ Ledergerber, B.; Egger, M.; Erard, V.; Weber, R.; Hirschel, B.; Furrer, H.; Battegay, M.; Vernazza, P.; Bernasconi, E. (Dec 15, 1999). "AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study". JAMA 282 (23): 2220–2226. doi:10.1001/jama.282.23.2220. ISSN 0098-7484. PMID 10605973. Retrieved 2015-05-09.
- ↑ Brooks, John T.; Kaplan, Jonathan E.; Holmes, King K.; Benson, Constance; Pau, Alice; Masur, Henry (Mar 1, 2009). "HIV-associated opportunistic infections--going, going, but not gone: the continued need for prevention and treatment guidelines". Clinical Infectious Diseases 48 (5): 609–611. doi:10.1086/596756. ISSN 1537-6591. PMID 19191648. Retrieved 2015-05-09.
- ↑ Freifeld, Alison G.; Bow, Eric J.; Sepkowitz, Kent A.; Boeckh, Michael J.; Ito, James I.; Mullen, Craig A.; Raad, Issam I.; Rolston, Kenneth V.; Young, Jo-Anne H. (Feb 15, 2011). "Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america". Clinical Infectious Diseases 52 (4): e56–93. doi:10.1093/cid/cir073. ISSN 1537-6591. PMID 21258094. Retrieved 2015-05-09.
- ↑ Smith, Thomas J.; Khatcheressian, James; Lyman, Gary H.; Ozer, Howard; Armitage, James O.; Balducci, Lodovico; Bennett, Charles L.; Cantor, Scott B.; Crawford, Jeffrey (Jul 1, 2006). "2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline". Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 24 (19): 3187–3205. doi:10.1200/JCO.2006.06.4451. ISSN 1527-7755. PMID 16682719. Retrieved 2015-05-09.
- ↑ "AIDSinfo: Recommendations to Help HIV-infected Patients Avoid Exposure to, or Infection from, Opportunistic Pathogens". 5/7/2013. Retrieved 2015-05-09. Check date values in:
|date=(help) - ↑ "AIDSinfo: Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents" (PDF). 2013-06-17. Retrieved 2015-05-09.